The University of Chicago Header Logo

Connection

Aytekin Oto to Prostatic Neoplasms

Back to Details
This is a "connection" page, showing publications Aytekin Oto has written about Prostatic Neoplasms.
Aytekin Oto
Connection Strength
18.353
Prostatic Neoplasms
  1. An Interactive App with Multi-parametric MRI - Whole-Mount Histology Correlation for Enhanced Prostate MRI Training of Radiology Residents. Acad Radiol. 2023 09; 30 Suppl 1:S21-S29.
    View in: PubMed
    Score: 0.409
  2. Comparing Radiologist Performance in Diagnosing Clinically Significant Prostate Cancer with Multiparametric versus Hybrid Multidimensional MRI. Radiology. 2022 11; 305(2):399-407.
    View in: PubMed
    Score: 0.388
  3. Physically implausible signals as a quantitative quality assessment metric in prostate diffusion-weighted MR imaging. Abdom Radiol (NY). 2022 07; 47(7):2500-2508.
    View in: PubMed
    Score: 0.383
  4. Prostate Tissue Microstructural Estimates Using Time-Dependent Diffusion MRI. Radiology. 2022 06; 303(3):588-589.
    View in: PubMed
    Score: 0.378
  5. Histological validation of prostate tissue composition measurement using hybrid multi-dimensional MRI: agreement with pathologists' measures. Abdom Radiol (NY). 2022 02; 47(2):801-813.
    View in: PubMed
    Score: 0.371
  6. Can Pre-treatment Quantitative Multi-parametric MRI Predict the Outcome of Radiotherapy in Patients with Prostate Cancer? Acad Radiol. 2022 07; 29(7):977-985.
    View in: PubMed
    Score: 0.367
  7. Effectiveness of Dynamic Contrast Enhanced MRI with a Split Dose of Gadoterate Meglumine for Detection of Prostate Cancer. Acad Radiol. 2022 06; 29(6):796-803.
    View in: PubMed
    Score: 0.366
  8. New prostate MRI techniques and sequences. Abdom Radiol (NY). 2020 12; 45(12):4052-4062.
    View in: PubMed
    Score: 0.346
  9. T2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy. Eur Radiol. 2021 Jan; 31(1):325-332.
    View in: PubMed
    Score: 0.339
  10. Factors Impacting Performance and Reproducibility of PI-RADS. Can Assoc Radiol J. 2021 08; 72(3):337-338.
    View in: PubMed
    Score: 0.338
  11. Prostate MR: pitfalls and benign lesions. Abdom Radiol (NY). 2020 07; 45(7):2154-2164.
    View in: PubMed
    Score: 0.336
  12. Effect of Echo Times on Prostate Cancer Detection on T2-Weighted Images. Acad Radiol. 2020 11; 27(11):1555-1563.
    View in: PubMed
    Score: 0.326
  13. Reply to "Prostate Cancer Index Lesion Detection and Volume Estimation: Is Dynamic Contrast-Enhanced MRI Really Reliable?" AJR Am J Roentgenol. 2019 12; 213(6):W290.
    View in: PubMed
    Score: 0.323
  14. Revisiting quantitative multi-parametric MRI of benign prostatic hyperplasia and its differentiation from transition zone cancer. Abdom Radiol (NY). 2019 06; 44(6):2233-2243.
    View in: PubMed
    Score: 0.312
  15. Diagnosis of Prostate Cancer by Use of MRI-Derived Quantitative Risk Maps: A Feasibility Study. AJR Am J Roentgenol. 2019 08; 213(2):W66-W75.
    View in: PubMed
    Score: 0.310
  16. Future Perspectives in Multiparametric Prostate MR Imaging. Magn Reson Imaging Clin N Am. 2019 Feb; 27(1):117-130.
    View in: PubMed
    Score: 0.305
  17. Comparison of T2-Weighted Imaging, DWI, and Dynamic Contrast-Enhanced MRI for Calculation of Prostate Cancer Index Lesion Volume: Correlation With Whole-Mount Pathology. AJR Am J Roentgenol. 2019 02; 212(2):351-356.
    View in: PubMed
    Score: 0.302
  18. Multiparametric MRI Features and Pathologic Outcome of Wedge-Shaped Lesions in the Peripheral Zone on T2-Weighted Images of the Prostate. AJR Am J Roentgenol. 2019 01; 212(1):124-129.
    View in: PubMed
    Score: 0.300
  19. MR Imaging-Guided Focal Therapies of Prostate Cancer. Magn Reson Imaging Clin N Am. 2019 Feb; 27(1):131-138.
    View in: PubMed
    Score: 0.299
  20. Evaluation of Focal Laser Ablation of Prostate Cancer Using High Spectral and Spatial Resolution Imaging: A Pilot Study. J Magn Reson Imaging. 2019 05; 49(5):1374-1380.
    View in: PubMed
    Score: 0.298
  21. MRI Findings After MRI-Guided Focal Laser Ablation of Prostate Cancer. AJR Am J Roentgenol. 2018 09; 211(3):595-604.
    View in: PubMed
    Score: 0.293
  22. Performance of T2 Maps in the Detection of Prostate Cancer. Acad Radiol. 2019 01; 26(1):15-21.
    View in: PubMed
    Score: 0.289
  23. Diagnosis of Prostate Cancer with Noninvasive Estimation of Prostate Tissue Composition by Using Hybrid Multidimensional MR Imaging: A Feasibility Study. Radiology. 2018 06; 287(3):864-873.
    View in: PubMed
    Score: 0.285
  24. Multiparametric MR Imaging of the Prostate after Treatment of Prostate Cancer. Radiographics. 2018 Mar-Apr; 38(2):437-449.
    View in: PubMed
    Score: 0.284
  25. Multiparametric MR imaging of the Prostate: Pitfalls in Interpretation. Radiol Clin North Am. 2018 Mar; 56(2):277-287.
    View in: PubMed
    Score: 0.282
  26. Prostate MR Imaging. Radiol Clin North Am. 2018 03; 56(2):xiii.
    View in: PubMed
    Score: 0.282
  27. MR Imaging of Prostate Zonal Anatomy. Radiol Clin North Am. 2018 Mar; 56(2):197-209.
    View in: PubMed
    Score: 0.281
  28. Performance of Ultrafast DCE-MRI for Diagnosis of Prostate Cancer. Acad Radiol. 2018 03; 25(3):349-358.
    View in: PubMed
    Score: 0.281
  29. Multi-parametric MR imaging of the anterior fibromuscular stroma and its differentiation from prostate cancer. Abdom Radiol (NY). 2017 03; 42(3):926-934.
    View in: PubMed
    Score: 0.267
  30. MRI-based prostate cancer detection with high-level representation and hierarchical classification. Med Phys. 2017 Mar; 44(3):1028-1039.
    View in: PubMed
    Score: 0.267
  31. MRI-guided focal therapy of prostate cancer. Future Oncol. 2017 Mar; 13(6):537-549.
    View in: PubMed
    Score: 0.260
  32. Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer. J Urol. 2016 12; 196(6):1670-1675.
    View in: PubMed
    Score: 0.256
  33. Pilot Study of the Use of Hybrid Multidimensional T2-Weighted Imaging-DWI for the Diagnosis of Prostate Cancer and Evaluation of Gleason Score. AJR Am J Roentgenol. 2016 Sep; 207(3):592-8.
    View in: PubMed
    Score: 0.255
  34. Endorectal MRI for risk classification of localized prostate cancer: Radiographic findings and influence on treatment decisions. Urol Oncol. 2016 09; 34(9):416.e15-21.
    View in: PubMed
    Score: 0.253
  35. Quantitative Multiparametric MRI Features and PTEN Expression of Peripheral Zone Prostate Cancer: A Pilot Study. AJR Am J Roentgenol. 2016 Mar; 206(3):559-65.
    View in: PubMed
    Score: 0.249
  36. Benign Conditions That Mimic Prostate Carcinoma: MR Imaging Features with Histopathologic Correlation. Radiographics. 2016 Jan-Feb; 36(1):162-75.
    View in: PubMed
    Score: 0.244
  37. Short-term reproducibility of apparent diffusion coefficient estimated from diffusion-weighted MRI of the prostate. Abdom Imaging. 2015 Oct; 40(7):2523-8.
    View in: PubMed
    Score: 0.242
  38. MRI-based prostate volume-adjusted prostate-specific antigen in the diagnosis of prostate cancer. J Magn Reson Imaging. 2015 Dec; 42(6):1733-9.
    View in: PubMed
    Score: 0.235
  39. Dynamic Contrast-enhanced MR Imaging Curve-type Analysis: Is It Helpful in the Differentiation of Prostate Cancer from Healthy Peripheral Zone? Radiology. 2015 May; 275(2):448-57.
    View in: PubMed
    Score: 0.230
  40. High-resolution diffusion-weighted imaging of the prostate. AJR Am J Roentgenol. 2014 Jul; 203(1):85-90.
    View in: PubMed
    Score: 0.222
  41. Dynamic contrast-enhanced MR imaging features of the normal central zone of the prostate. Acad Radiol. 2014 May; 21(5):569-77.
    View in: PubMed
    Score: 0.219
  42. Apparent diffusion coefficient for prostate cancer imaging: impact of B values. AJR Am J Roentgenol. 2014 Mar; 202(3):W247-53.
    View in: PubMed
    Score: 0.217
  43. Validation of quantitative analysis of multiparametric prostate MR images for prostate cancer detection and aggressiveness assessment: a cross-imager study. Radiology. 2014 May; 271(2):461-71.
    View in: PubMed
    Score: 0.216
  44. Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancer. AJR Am J Roentgenol. 2013 Nov; 201(5):1041-8.
    View in: PubMed
    Score: 0.212
  45. MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology. 2013 Jun; 267(3):932-40.
    View in: PubMed
    Score: 0.202
  46. Seminal vesicle invasion in prostate cancer: evaluation by using multiparametric endorectal MR imaging. Radiology. 2013 Jun; 267(3):797-806.
    View in: PubMed
    Score: 0.202
  47. Quantitative analysis of multiparametric prostate MR images: differentiation between prostate cancer and normal tissue and correlation with Gleason score--a computer-aided diagnosis development study. Radiology. 2013 Jun; 267(3):787-96.
    View in: PubMed
    Score: 0.201
  48. Microvessel density is not increased in prostate cancer: digital imaging of routine sections and tissue microarrays. Hum Pathol. 2013 Apr; 44(4):495-502.
    View in: PubMed
    Score: 0.197
  49. Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):378-84.
    View in: PubMed
    Score: 0.193
  50. Local staging of prostate cancer with MRI. Diagn Interv Radiol. 2012 Jul-Aug; 18(4):365-73.
    View in: PubMed
    Score: 0.189
  51. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol. 2011 Dec; 197(6):1382-90.
    View in: PubMed
    Score: 0.185
  52. High-resolution MRI of excised human prostate specimens acquired with 9.4T in detection and identification of cancers: validation of a technique. J Magn Reson Imaging. 2011 Oct; 34(4):956-61.
    View in: PubMed
    Score: 0.183
  53. Invited commentary. Radiographics. 2011 May-Jun; 31(3):704-6; discussion 706.
    View in: PubMed
    Score: 0.178
  54. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology. 2010 Dec; 257(3):715-23.
    View in: PubMed
    Score: 0.171
  55. Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer. Top Magn Reson Imaging. 2009 Apr; 20(2):105-12.
    View in: PubMed
    Score: 0.154
  56. Four-quadrant vector mapping of hybrid multidimensional MRI data for the diagnosis of prostate cancer. Med Phys. 2024 Mar; 51(3):2057-2065.
    View in: PubMed
    Score: 0.105
  57. Parametric maps of spatial two-tissue compartment model for prostate dynamic contrast enhanced MRI - comparison with the standard tofts model in the diagnosis of prostate cancer. Phys Eng Sci Med. 2023 Sep; 46(3):1215-1226.
    View in: PubMed
    Score: 0.104
  58. Improving reader accuracy and specificity with the addition of hybrid multidimensional-MRI to multiparametric-MRI in diagnosing clinically significant prostate cancers. Abdom Radiol (NY). 2023 10; 48(10):3216-3228.
    View in: PubMed
    Score: 0.103
  59. ACR Appropriateness Criteria® Post-Treatment Follow-up of Prostate Cancer: 2022 Update. J Am Coll Radiol. 2023 05; 20(5S):S164-S186.
    View in: PubMed
    Score: 0.102
  60. ACR Appropriateness Criteria® Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update. J Am Coll Radiol. 2023 05; 20(5S):S187-S210.
    View in: PubMed
    Score: 0.102
  61. Directional and inter-acquisition variability in diffusion-weighted imaging and editing for restricted diffusion. Magn Reson Med. 2022 11; 88(5):2298-2310.
    View in: PubMed
    Score: 0.097
  62. Validation of Prostate Tissue Composition by Using Hybrid Multidimensional MRI: Correlation with Histologic Findings. Radiology. 2022 02; 302(2):368-377.
    View in: PubMed
    Score: 0.092
  63. MRI Targeted Prostate Biopsy Techniques: AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2021 12; 217(6):1263-1281.
    View in: PubMed
    Score: 0.090
  64. Prostate minimally invasive procedures: complications and normal vs. abnormal findings on multiparametric magnetic resonance imaging (mpMRI). Abdom Radiol (NY). 2021 09; 46(9):4388-4400.
    View in: PubMed
    Score: 0.089
  65. High spectral and spatial resolution MRI of prostate cancer: a pilot study. Magn Reson Med. 2021 09; 86(3):1505-1513.
    View in: PubMed
    Score: 0.089
  66. Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus -based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical Prostatectomy. Eur Urol Oncol. 2021 12; 4(6):868-876.
    View in: PubMed
    Score: 0.088
  67. Signal intensity form of the Tofts model for quantitative analysis of prostate dynamic contrast enhanced MRI data. Phys Med Biol. 2021 01 22; 66(2):025002.
    View in: PubMed
    Score: 0.087
  68. PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy-Naive Men With Suspected Prostate Cancer: Narrative Review. AJR Am J Roentgenol. 2021 01; 216(1):3-19.
    View in: PubMed
    Score: 0.086
  69. Data Augmentation and Transfer Learning to Improve Generalizability of an Automated Prostate Segmentation Model. AJR Am J Roentgenol. 2020 12; 215(6):1403-1410.
    View in: PubMed
    Score: 0.086
  70. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. J Urol. 2021 Mar; 205(3):769-779.
    View in: PubMed
    Score: 0.086
  71. Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology. 2020 07; 296(1):76-84.
    View in: PubMed
    Score: 0.083
  72. Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. J Clin Oncol. 2020 06 10; 38(17):1963-1996.
    View in: PubMed
    Score: 0.081
  73. PI-RADS score is associated with biochemical control and distant metastasis in men with intermediate-risk and high-risk prostate cancer treated with radiation therapy. Urol Oncol. 2020 06; 38(6):600.e1-600.e8.
    View in: PubMed
    Score: 0.081
  74. A compact solution for estimation of physiological parameters from ultrafast prostate dynamic contrast enhanced MRI. Phys Med Biol. 2019 08 07; 64(15):155012.
    View in: PubMed
    Score: 0.079
  75. Use of Indicator Dilution Principle to Evaluate Accuracy of Arterial Input Function Measured With Low-Dose Ultrafast Prostate Dynamic Contrast-Enhanced MRI. Tomography. 2019 06; 5(2):260-265.
    View in: PubMed
    Score: 0.078
  76. Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project. World J Urol. 2019 Oct; 37(10):2147-2153.
    View in: PubMed
    Score: 0.076
  77. Evaluation of tumor coverage after MR-guided prostate focal laser ablation therapy. Med Phys. 2019 Feb; 46(2):800-810.
    View in: PubMed
    Score: 0.075
  78. Feasibility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Low-Dose Gadolinium: Comparative Performance With Standard Dose in Prostate Cancer Diagnosis. Invest Radiol. 2018 10; 53(10):609-615.
    View in: PubMed
    Score: 0.074
  79. Pretreatment multiparametric MRI is independently associated with biochemical outcome in men treated with radiation therapy for prostate cancer. Urol Oncol. 2018 10; 36(10):471.e11-471.e18.
    View in: PubMed
    Score: 0.074
  80. A Magnetic Resonance Imaging-Based Prediction Model for Prostate Biopsy Risk Stratification. JAMA Oncol. 2018 05 01; 4(5):678-685.
    View in: PubMed
    Score: 0.072
  81. ACR Appropriateness Criteria® Post-treatment Follow-up Prostate Cancer. J Am Coll Radiol. 2018 May; 15(5S):S132-S149.
    View in: PubMed
    Score: 0.072
  82. Comparison of arterial input functions measured from ultra-fast dynamic contrast enhanced MRI and dynamic contrast enhanced computed tomography in prostate cancer patients. Phys Med Biol. 2018 01 30; 63(3):03NT01.
    View in: PubMed
    Score: 0.071
  83. The Current State of MR Imaging-targeted Biopsy Techniques for Detection of Prostate Cancer. Radiology. 2017 11; 285(2):343-356.
    View in: PubMed
    Score: 0.070
  84. Comparison of region-of-interest-averaged and pixel-averaged analysis of DCE-MRI data based on simulations and pre-clinical experiments. Phys Med Biol. 2017 Sep 05; 62(18):N445-N459.
    View in: PubMed
    Score: 0.069
  85. ACR Appropriateness Criteria® Prostate Cancer-Pretreatment Detection, Surveillance, and Staging. J Am Coll Radiol. 2017 May; 14(5S):S245-S257.
    View in: PubMed
    Score: 0.067
  86. In vivo MRI based prostate cancer localization with random forests and auto-context model. Comput Med Imaging Graph. 2016 09; 52:44-57.
    View in: PubMed
    Score: 0.062
  87. Prostate Imaging Reporting and Data System (PI-RADS), Version 2: A Critical Look. AJR Am J Roentgenol. 2016 Jun; 206(6):1179-83.
    View in: PubMed
    Score: 0.062
  88. Arterial input functions (AIFs) measured directly from arteries with low and standard doses of contrast agent, and AIFs derived from reference tissues. Magn Reson Imaging. 2016 Feb; 34(2):197-203.
    View in: PubMed
    Score: 0.061
  89. Giant Multilocular Cystadenoma of the Prostate. Radiographics. 2015 Jul-Aug; 35(4):1051-5.
    View in: PubMed
    Score: 0.059
  90. Laser ablation as focal therapy for prostate cancer. Curr Opin Urol. 2014 May; 24(3):236-40.
    View in: PubMed
    Score: 0.055
  91. MR imaging of the prostate. Radiol Clin North Am. 2014 Jul; 52(4):811-37.
    View in: PubMed
    Score: 0.055
  92. Cross-device automated prostate cancer localization with multiparametric MRI. IEEE Trans Image Process. 2013 12; 22(12):5385-94.
    View in: PubMed
    Score: 0.053
  93. Revisiting the central gland anatomy via MRI: does the central gland extend below the level of verumontanum? J Magn Reson Imaging. 2014 Jan; 39(1):167-71.
    View in: PubMed
    Score: 0.053
  94. Hybrid multidimensional T(2) and diffusion-weighted MRI for prostate cancer detection. J Magn Reson Imaging. 2014 Apr; 39(4):781-8.
    View in: PubMed
    Score: 0.052
  95. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol. 2013 Oct; 64(4):544-52.
    View in: PubMed
    Score: 0.051
  96. ACR Appropriateness Criteria prostate cancer--pretreatment detection, staging, and surveillance. J Am Coll Radiol. 2013 Feb; 10(2):83-92.
    View in: PubMed
    Score: 0.050
  97. Representation learning: a unified deep learning framework for automatic prostate MR segmentation. Med Image Comput Comput Assist Interv. 2013; 16(Pt 2):254-61.
    View in: PubMed
    Score: 0.050
  98. Automatic prostate MR image segmentation with sparse label propagation and domain-specific manifold regularization. Inf Process Med Imaging. 2013; 23:511-23.
    View in: PubMed
    Score: 0.050
  99. Cross-device automated prostate cancer localization with multiparametric MRI. Annu Int Conf IEEE Eng Med Biol Soc. 2012; 2012:6247-50.
    View in: PubMed
    Score: 0.047
  100. Reproducibility assessment of a multiple reference tissue method for quantitative dynamic contrast enhanced-MRI analysis. Magn Reson Med. 2009 Apr; 61(4):851-9.
    View in: PubMed
    Score: 0.039
  101. Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging. Eur Urol Oncol. 2019 05; 2(3):257-264.
    View in: PubMed
    Score: 0.019
  102. ACR Appropriateness Criteria® Hematospermia. J Am Coll Radiol. 2017 May; 14(5S):S154-S159.
    View in: PubMed
    Score: 0.017
  103. Deformable segmentation of 3D MR prostate images via distributed discriminative dictionary and ensemble learning. Med Phys. 2014 Jul; 41(7):072303.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.